Pet cancer care is a five-figure expense. Chemotherapy runs about $3,000 to $10,000 across a full protocol, radiation $4,500 to $6,000 for a curative course and up to $10,000 or more, and chemotherapy plus radiation together can reach $10,000 to $20,000, per CareCredit's 2025 cost research [CareCredit Dog and Cat Chemotherapy Cost and Financing, 2025]. The reason this page exists separate from the others is the annual limit: cancer is the claim where a low policy cap quietly fails the buyer who thought they were covered. This page covers the cost and the coverage math, not the care.
The cost range for cancer care
CareCredit's cost study, run by ASQ360 in 2025 across the 50 states and the District of Columbia, breaks the spend into components. A single chemotherapy dose averages $150 to $600, and a full protocol over four to six months totals $3,000 to $10,000 or more [CareCredit Dog and Cat Chemotherapy Cost and Financing, 2025]. Radiation is priced separately: a palliative protocol runs $1,000 to $1,800, and a curative-intent protocol $4,500 to $6,000, with the full chemotherapy course itself reaching $10,000 or more [CareCredit Dog and Cat Chemotherapy Cost and Financing, 2025]. The oncology consult that opens the file is $125 to $250 on its own [CareCredit Dog and Cat Chemotherapy Cost and Financing, 2025].
Combined, those components are why a single chemotherapy course commonly clears $10,000, and adding a curative radiation protocol on top pushes a combined-modality case toward $20,000 [CareCredit Dog and Cat Chemotherapy Cost and Financing, 2025].
Why totals run into five figures
Cancer is not one bill. It is a sequence: the consult, staging diagnostics, then a months-long protocol of repeated doses, often with imaging between rounds. Each line is modest; the cumulative total over four to six months is what reaches five figures [CareCredit Dog and Cat Chemotherapy Cost and Financing, 2025]. Two cost drivers widen the band: the modality, since combination chemo-and-radiation roughly doubles a single-modality total, and dog size, since dose scales with weight.
The structural problem this creates for insurance is duration. A claim that spans many months can outrun a calendar-year policy limit.
What a policy would have covered
Here is where the annual limit decides everything. On a $12,000 cancer course with an accident-and-illness policy at 80 percent reimbursement and a $500 annual deductible, the policy returns about 80 percent of the $11,500 above the deductible, roughly $9,200, if the annual limit is high enough to absorb it.
It often is not. A policy with a $5,000 annual payout cap stops reimbursing at $5,000 no matter the reimbursement rate, leaving the owner with $7,000 of a $12,000 course out of pocket. If treatment straddles two policy years the cap may reset, but a single-year protocol does not get that reset. This is the objection cancer exposes that the headline premium hides: the annual limit, not the reimbursement percentage, is the term that fails on a long high-cost claim. FurVerdict treats annual-limit structure as a primary factor in its review; the breakdown is at /coverage/.
A $12,000 cancer course, 80 percent reimbursement, $500 deductible. With an unlimited or high annual limit the policy returns roughly $9,200. With a $5,000 annual cap it returns $5,000 and the owner absorbs $7,000. The reimbursement rate is identical; the annual limit is the entire difference [CareCredit Dog and Cat Chemotherapy Cost and Financing, 2025].
The timing constraint applies as it does everywhere: a policy bought after a cancer is on the record does not cover that cancer, because it is then a pre-existing condition. The math above only works for a policy held, with an adequate annual limit, before the cancer is on the record.
The bottom line
Cancer care is a $3,000-to-$20,000 expense that unfolds over months, and the term that decides whether a policy absorbs it is the annual limit, not the reimbursement rate the marketing leads with. A buyer pricing this risk should weigh annual-limit structures first, against the annual-limit analysis at /coverage/. FurVerdict's review method is published at /methodology/, and /disclosure/ explains how the affiliate relationship is handled. This page is reviewed every 180 days and on any cited cost-data change.